In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
about
"Stormy waters ahead": global emergence of carbapenemasesCurrent concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaEmergence of Klebsiella pneumoniae carbapenemase-producing bacteriaFosfomycin: A First-Line Oral Therapy for Acute Uncomplicated CystitisInsights into Newer Antimicrobial Agents Against Gram-negative BacteriaAntimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.Etiological and Resistance Profile of Bacteria Involved in Urinary Tract Infections in Young Children.The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignanciesFosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany.Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymesCarbapenemase-producing Klebsiella pneumoniae.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensCarbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patientsEmerging rapid resistance testing methods for clinical microbiology laboratories and their potential impact on patient management.Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniaeTreatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort.Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase.Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections.Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methodsPolymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases.Carbapenemase-producing Enterobacteriaceae.Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae.Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China.Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsExperience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.FosfomycinMultidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Fosfomycin: Resurgence of an old companion.Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Status report on carbapenemases: challenges and prospects.Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.Surveillance and management of multidrug-resistant microorganisms.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?KPC screening by updated BD Phoenix and Vitek 2 automated systems.Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.Role of old antimicrobial agents in the management of urinary tract infection.
P2860
Q21131125-1B68008D-394D-4BE0-A9FF-7B91352B774AQ24612271-47EB34BC-A9FB-4778-A9C5-82C5463F4122Q24618178-20ABEADD-DA24-4452-9709-6F88035F8695Q26745740-FC351F55-60E9-4724-AC11-11469C9204A0Q26751255-B9FA9244-B154-4FC8-801E-A7B15B35A1DDQ33593516-7790DA88-27FF-4A4B-988C-2F79467562E3Q33603991-2354E01A-E843-4B9C-8023-940FECC7573FQ33686940-209A95F3-6AC2-4C64-A43B-6C2D286F84D2Q33703401-13FFE1FD-1EDE-4B7A-BB2E-C737A3E213C9Q33962732-67D2F5F0-D9F0-49CD-9C93-17420E0A015BQ34201937-1C93377C-3B18-4ABE-BA62-F03FEFD1F0CFQ34303970-A5868E02-5D28-4FFA-BE72-041A60F0AD27Q34336456-233D1A0C-8275-41B4-915E-8D0F5D046F94Q34342514-52F76B24-37EF-49A5-9291-7A879F764FBDQ34483491-91F2558A-9620-405F-8E1E-610ACA5CE293Q34906223-7C0BFADB-8C5A-4FD3-8ACC-2BE172BC3A19Q35019811-6C120A80-F0CA-495C-AD12-9ACE08EC0520Q35106776-529FC10E-C9D4-41FE-959F-0E9EB587CDDAQ35191584-BBFFE213-04FD-468B-A622-292D96454CFFQ35585019-CE3F0D53-B947-4F3E-AA3B-143167B2B497Q35751615-476EAFBC-A0F2-4A58-8F53-D9C0E481C0F5Q35859981-A1D7DBD5-13AB-4026-AF58-DAA3B5E9C5C4Q35867426-F096FDD1-0E59-4461-8B01-18139F6BFE24Q36290521-0448FFBB-2EF3-41EE-8142-D6D2CDA73E2BQ36361921-F4F1026E-7153-4597-8D4C-3D6D2371CB73Q36364199-E569091F-6B94-47E6-A201-9F70E0F81043Q36675246-DFB05479-8CDC-4151-91FE-41833ECF6526Q36761826-E5A55EBC-2991-46A9-AD6C-EF5A8AEC7EBDQ36803694-D048D417-128C-41C8-853F-CEC7CF7C17A2Q37146405-BB51790E-858B-4F92-A7A0-4B264166F2E8Q37879199-1DDFADE2-D943-47D4-87FC-A1D6B90D9A05Q37894694-1D5E110D-238F-4676-B258-4194914AE240Q37907967-0C0719A4-1AA6-48C2-8D7D-31B2551CDFF4Q37912231-E65FC61E-E9F6-417A-8D3F-85E921C1D760Q38208281-D955148B-ED13-4592-9396-3E61ACA3657CQ38231648-2CD6688E-592B-4367-A0CD-6432C693239DQ38285014-3164A4B4-AFD5-4FA0-A428-BB23ABA52A1EQ38325217-68172143-FA2D-487F-AAEA-EDA2BCA816E1Q38392082-7F25DE99-62AD-4AC2-8B8C-6ED82E39207DQ38832723-5C90399F-B00F-42F2-898E-7D23385F484F
P2860
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@ast
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@en
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@nl
type
label
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@ast
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@en
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@nl
prefLabel
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@ast
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@en
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@nl
P2093
P2860
P356
P1476
In vitro activity of fosfomyci ...... o tigecycline and/or colistin.
@en
P2093
Federico Perez
Gopi Patel
Kristine M Hujer
Louis B Rice
Mahesh Swaminathan
Michael R Jacobs
P2860
P304
P356
10.1128/AAC.01235-09
P407
P577
2009-11-09T00:00:00Z